by Tara Green

May 28, 2011
from NaturalNews Website

 

 

 

As DEA raids and IRS harassment continue on state-approved medical marijuana, Big Pharma eyes the profitability of cannabis and prepares to muscle in, using its lobbyists and government connections to ensure a monopoly on legal sales of the drug.

In early April of 2011, two drug manufacturing giants, G.W. Pharmaceuticals and Novartis, announced they had formed an alliance to license and market GW's Sativex, a liquid cannabis drug.

 

The drug is already available in Great Britain, as well as Canada and Spain. The licensing agreement with Novartis will enable sales to expand into markets in Africa, Asia and the Middle East.

 

FDA Phase III trials are still being organized for Otsuka, GW's partner for licensing Sativex for the US market.

Unlike other cannaboids produced for recreational or medicinal use, Sativex is not a synthetic but an actual extract of the cannabis plant. It therefore lacks the side-effects of the synthetic drugs which merely attempt to replicate cannabis. Patients, primarily people diagnosed with MS or cancer, spray Sativex beneath their tongues.

GW claims that Sativex is formulated to provide the same health benefits that medical marijuana offers but without that drug's high.

 

GW says that Sativex balances the psychoactive agent THC with cannabidiol (CBD), the chemical believed to be the source of medical marijuana's anti-nausea and cancer-cell-killing effects, in such a way as to eliminate any of the sensations associated with recreational marijuana.

 

However, cannabis expert Dr. Lester Grinspoon, professor emeritus of psychiatry at Harvard Medical School, points out that the issue of whether Sativex produces marijuana high depends on the size of the dosage.

One of GW's allies in its attempt to replace state-legalized whole-plant medical marijuana with its own chemical extract is Dr. Andrea Barthwell whose career includes consulting for GW, as well as stints as deputy drug czar under President George W. Bush and as president of the American Society for Addiction Medicine.

 

Barthwell frames Big Pharma cannabis as best way to bring marijuana into medical usage:

"The safety and advisability of any prescriptive medicine should depend on years of careful scientific scrutiny, not whims at the ballot box by individuals who lack the qualifications to make such decisions. Allowing cannabis to circumvent FDA approval sets a dangerous precedent and puts us on a slippery slope."

Big Pharma's big contributions to many legislators means they have many elected officials willing to see things the drug companies' way on this, as on many other issues.

 

Even legislators known to take a strong states' right stance on other issues, such as offshore drilling, somehow find themselves standing up for federal oversight on this topic.

 

For example, Sen. Richard Burr (R-N.C.), who holds the dubious distinction of the being the member of Congress who has accepted the largest amount from pharmaceutical firms, has taken a stance against state legalization of marijuana.

If you have a politician in your state who speaks out against medical marijuana, you may want to look into his/her ties to Big Pharma.

 

As the American Independent observes, the pharmaceutical giants' strategy as regards marijuana seems to be,

"demonize it, prosecute it, shut it down, then grab the market."

Let your friends and family know that many of those who fight against medical marijuana are not, as they may prefer to present themselves, taking a pro-family stance against drug addiction, but shills for multinational drug corporations who want to keep all drug profits in their coffers.

The idea that a drug can be denounced as evil in one context but hailed as a medical miracle if sold within the pharmaceutical system is nothing new. Big Pharma's magic cure pills for ADHD bear a suspicious chemical resemblance to speed.

As consumer health advocate and critic of federal drug policy Mike Adams has pointed out elsewhere in NaturalNews, this double standard, with multinational corporations valued above the health of private citizens, has a pernicious effect on our culture,

"While dangerous prescription drugs are killing a hundred thousand Americans each year, the DEA does nothing. But when herb smokers light up in private, they are branded criminals and subject to a form of tyranny and oppression that should never be tolerated in a free society."


 

Sources

 

 

 

 

 

 

 


 Groups Push Obama Administration to...

Reschedule Marijuana After Nine Years of Needless Delay
by Jonathan Benson

staff writer
May 28, 2011

from NaturalNews Website


The gap between many individual state laws regulating marijuana and the overarching federal intolerance of the plant is widening, and a coalition of marijuana advocacy groups has filed a lawsuit in the US Court of Appeals for the District of Columbia Circuit to push the Obama administration to respond to a nine-year-old petition to have marijuana rescheduled under the Controlled Substance Act (CSA).

 

According to the Coalition for Rescheduling Cannabis (CRC), the federal government has violated the Administrative Procedures Act by failing to respond to the petition within a reasonable amount of time.

Sixteen states and the District of Columbia (DC) now accept that marijuana has a legitimate medical use, and many others are beginning to adopt this position as well.

 

But the federal government continues to unfairly recognize marijuana as a Schedule I substance, which falsely deems it a medically-useless, highly-abused drug in the same vein as heroin and ecstasy.

"Marijuana has accepted medical use in the United States, it has a lower abuse potential than drugs like heroin, methamphetamine, and cocaine, and it is safe for use under medical supervision," said Jon Gettman, CDC coordinator.

 

"All of these characteristics are well-documented scientifically and legally. Federal law requires the Obama administration to reclassify marijuana."

Gettman also emphasized that the administration's failure to address the issue is an unlawful denial of due process.

 

One way or another, the federal government is required by law to acknowledge the petition and formulate a proper response; it cannot simply ignore it and continue to intimidate states where marijuana has been legalized with threats of regulatory crackdowns.

The coalition is also questioning the federal government's double standard for marijuana, since it has given Marinol, a synthetic, pharmaceutical version of the tetrahydrocannabinol (THC) found in marijuana, medical approval and classification as a Schedule III drug, while continuing to discriminate against natural marijuana.

 

Such an arrangement, of course, clearly illustrates the federal government's obvious bias in favor of patented drugs that have gone through the million-dollar FDA approval process.

 


Source